FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
For Immediate Release: August 05, 2022 Today, the US Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with… Read More »FDA Approves First Targeted Therapy for HER2-Low Breast Cancer